

Hong-Jae Chon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5735992/publications.pdf>

Version: 2024-02-01

56
papers

1,880
citations

304701

22
h-index

302107

39
g-index

56
all docs

56
docs citations

56
times ranked

2716
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1475-1485.	7.7	306
2	STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. <i>Journal of Clinical Investigation</i> , 2019, 129, 4350-4364.	8.2	178
3	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	2.6	124
4	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	3.7	122
5	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 1612-1623.	7.0	120
6	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 946-953.	4.2	117
7	STING signaling is a potential immunotherapeutic target in colorectal cancer. <i>Journal of Cancer</i> , 2019, 10, 4932-4938.	2.5	51
8	STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. , 2021, 9, e002195.		49
9	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 385.	2.6	46
10	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9414.	4.1	46
11	Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. <i>Liver Cancer</i> , 2020, 9, 613-624.	7.7	45
12	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 674-681.	3.9	39
13	Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. , 2020, 8, e000857.		37
14	Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7743.	4.1	36
15	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>Cancers</i> , 2022, 14, 1747.	3.7	36
16	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501.	1.8	34
17	Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3123.	3.7	33
18	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	3.9	32

#	ARTICLE	IF	CITATIONS
19	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8035.	4.1	30
20	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987112.	3.2	27
21	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. <i>Cancer</i> , 2022, 128, 995-1003.	4.1	27
22	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. <i>Liver International</i> , 2020, 40, 2263-2271.	3.9	26
23	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196.	3.0	25
24	Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1127-1139.	3.0	25
25	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. <i>Clinical Colorectal Cancer</i> , 2018, 17, e513-e518.	2.3	24
26	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). <i>ESMO Open</i> , 2021, 6, 100049.	4.5	21
27	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4906.	3.7	18
28	Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. <i>Journal of Cancer</i> , 2016, 7, 1550-1556.	2.5	16
29	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 113-122.	5.3	16
30	Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. <i>Gene Therapy</i> , 2021, 28, 186-198.	4.5	16
31	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , 2017, 125, 223-229.	2.0	15
32	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092342.	3.2	14
33	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. , 2021, 9, e003353.		14
34	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3938-3945.	1.5	13
35	Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110359.	3.2	13
36	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2051-2059.	2.5	12

#	ARTICLE	IF	CITATIONS
37	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	3.2	10
38	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. <i>Cancers</i> , 2022, 14, 3213.	3.7	10
39	Robotic transduodenal ampullectomy: A novel minimally invasive approach for ampullary neoplasms. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2019, 15, e1979.	2.3	8
40	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210979.	3.2	7
41	Optimal Voltage and Electrical Pulse Conditions for Electrical Ablation to Induce Immunogenic Cell Death (ICD). <i>Journal of Industrial and Engineering Chemistry</i> , 2021, 94, 225-232.	5.8	6
42	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10565-10565.	1.6	6
43	Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. <i>Oncolmmunology</i> , 2021, 10, 2005280.	4.6	6
44	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3015-3015.	1.6	5
45	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 991-999.	2.3	4
46	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4161-TPS4161.	1.6	4
47	Abstract 1914: Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer. , 2021, , .		3
48	A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients. <i>Supportive Care in Cancer</i> , 2022, 30, 6103-6112.	2.2	3
49	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28.	2.8	2
50	REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2020, 9, 58-58.	1.2	1
51	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 689-689.	1.6	1
52	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 344-344.	1.6	1
53	Characterization of hyperprogressive disease in patients with advanced biliary tract cancer treated with anti-PD-1 inhibitor: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 339-339.	1.6	0
54	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15020-e15020.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4113-4113.	1.6	0
56	Efficacy and safety of lenvatinib (LEN) in Korean patients (pts) with advanced hepatocellular carcinoma (aHCC): Multicenter retrospective analysis.. Journal of Clinical Oncology, 2020, 38, 490-490.	1.6	0